What type of drug does Vemurafenib/Zorbovo Tablets belong to?

Vemurafenib/zobovo(Vemurafenib) is a small molecule BRAF inhibitor and an important representative of melanoma treatment. It was developed from the discovery of the critical role of BRAF gene mutations in malignant melanoma. Research shows that about half of melanoma patients carry the BRAF V600E mutation. This mutation causes the MAPK/ERK signaling pathway to be continuously activated, allowing cancer cells to continuously divide and evade normal regulatory mechanisms. Vemurafenib effectively blocks this pathway and inhibits tumor progression by precisely binding to the mutant BRAF protein.

From the perspective of drug classification, vemurafenib belongs to the category of "molecular targeted drugs", which are drugs that specifically target specific molecular changes in tumor cells to inhibit them. Unlike traditional chemotherapy drugs, it does not kill all rapidly dividing cells indiscriminately, but uses a highly selective mechanism of action to minimize damage to normal tissues. Therefore, it improves the safety and accuracy of treatment to a certain extent. In addition to melanoma, vemurafenib has also been explored in some other tumors with BRAF mutations, but its application in melanoma is currently the most mature.

It is worth mentioning that although vemurafenib can quickly control the disease as a single drug, drug resistance may occur with long-term use because cancer cells will evade BRAF inhibition through the activation of other signaling pathways . Therefore, it is often used in combination with MEK inhibitors in clinical practice to delay the emergence of drug resistance. This combined treatment strategy has gradually become a standard regimen recommended by international guidelines. It can be said that vemurafenib is not only a drug, but also a landmark breakthrough in the era of targeted therapy. Its emergence has transformed BRAF-mutated melanoma from "almost incurable" to "can be precisely managed", which has greatly changed the prognosis of patients and promoted the rapid development of molecular medicine in the field of cancer.

Reference: https://www.drugs.com/mtm/vemurafenib.html